# US 2010/0166850 A1 · Eprosartan mesylate crystalline particles and a process for preparing pure eprosartan

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166850 A1
- Document ID: US20100166850A1
- Status: Published application
- Kind: A1
- Application number: 11/993,513
- Filed: 2007-07-25
- Published: 2010-07-01
- Earliest claimed: 2007-07-25
- Assignees: Hetero Drugs Limited
- Inventors: Bandi Parthasaradhi Reddy; Kura Rathnakar Reddy; Rapolu Raji Reddy; Dasari Muralidhara Reddy; Medabalimi Peter Paul Raj
- Web page: https://patentgrep.com/patent/US20100166850A1

## CPC

- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to eprosartan mesylate particles having relatively larger surface area, to the methods for the manufacture of said crystalline particles, and to pharmaceutical compositions comprising said crystalline particles. The present invention further relates to crystalline solid of eprosartan acetate, to a process for its preparation and to a pharmaceutical composition comprising it. The present invention also provides substantially pure eprosartan free base and process for its preparation.

## Claims

### Claim 1

Crystalline particles of eprosartan mesylate having a specific surface area of from about 0.65 m2/g to about 3 m2/g.

### Claim 2 (depends on 1)

The crystalline particles of eprosartan mesylate as claimed in claim 1, wherein the particles have mean particle size (D50) ranges from about 7 μm to 50 μm and 90 volume-% of the particles (D90) ranges from about 21 μm to 150 μm.

### Claim 3 (depends on 1)

A process for the preparation of eprosartan mesylate crystalline particles having a specific surface area of from about 0.65 m2/g to about 3 m2/g as defined in claim 1, which comprises:
a) suspending eprosartan free base or its acetate salt in a ketonic solvent;
b) adding methanesulfonic acid slowly to the suspension obtained in step (a) at a temperature below 10° C.; and
c) collecting the precipitated eprosartan mesylate crystalline particles having a specific surface area of from about 0.65 m2/g to about 3 m2/g.

### Claim 4 (depends on 3)

The process as claimed in claim 3, wherein the ketonic solvent is selected from the group consisting of acetone, methyl ethyl ketone, methyl isobutyl ketone, methyl isopropyl ketone, methyl tert-butyl ketone.

### Claim 5 (depends on 4)

The process as claimed in claim 4, wherein the ketonic solvent is acetone.

### Claim 6 (depends on 3)

The process as claimed in claim 3, wherein the solution formed after addition of methanesulfonic acid in step (b) is stirred at least for about 1 hour at 20-30° C.

### Claim 7 (depends on 6)

The process as claimed in claim 6, wherein the solution is stirred at least for about 1 hour 30 minutes at 20-30° C.

### Claim 8 (depends on 7)

The process as claimed in claim 7, wherein the solution is stirred for about 2 hours to 6 hours at 20-30° C.

### Claim 9 (depends on 3)

The process as claimed in claim 3, wherein the precipitated eprosartan mesylate crystalline particles in step (c) are collected by filtration or centrifugation.

### Claim 10 (depends on 3)

The process as claimed in claim 3, wherein the eprosartan mesylate particles obtained in step (c) have a specific surface area of from about 0.7 to 2.5 m2/g.

### Claim 11 (depends on 10)

The process as claimed in claim 10, wherein the eprosartan mesylate particles have a specific surface area of from about 0.8 to 2.0 m2/g.

### Claim 12 (depends on 3)

The process as claimed in claim 3, wherein the eprosartan mesylate particles obtained in step (c) have mean particle size (D50) ranges from about 10 μm to 30 μm and 90 volume-% of the particles (D90) ranges from about 22 μm to 120 μm.

### Claim 13 (depends on 12)

The process as claimed in claim 12, wherein eprosartan mesylate particles have mean particle size (D50) ranges from about 10 μm to 25 μm and 90 volume-% of the particles (D90) ranges from about 25 μm to 60 μm.

### Claim 14 (depends on 13)

The process as claimed in claim 13, wherein eprosartan mesylate particles have mean particle size (D50) ranges from about 11 μm to 20 μm and 90 volume-% of the particles (D90) ranges from about 26 μm to 50 μm.

### Claim 15

Crystalline solid of eprosartan acetate.

### Claim 16 (depends on 15)

The compound as claimed in claim 15, wherein the crystalline solid of eprosartan acetate is characterized by an X-ray powder diffraction pattern having peaks expressed as 2θ angle positions at about 8.1, 10.7, 14.5, 16.7, 17.8, 21.4, 22.5, 23.6, 24.6, 26.1 and 28.4±0.2 degrees.

### Claim 17 (depends on 15)

The compound as claimed in claim 15, wherein the crystalline solid of eprosartan acetate is further characterized by a Differential Scanning Calorimetry (DSC) thermogram having a small endotherm 110° C. followed by a sharp endotherm at 266° C.

### Claim 18 (depends on 15)

A process for the preparation of crystalline solid of eprosartan acetate as defined in claim 15, which comprises:
i. dissolving crude eprosartan free base in acetic acid;
ii. adding methylene chloride slowly to the filtrate obtained in step (a) at a temperature below about 40° C.; and
iii. collecting the precipitated eprosartan acetate crystalline solid.

### Claim 19 (depends on 18)

The process as claimed in claim 18, wherein the purity of the eprosartan acetate obtained in step (c) is about above 99%.

### Claim 20 (depends on 19)

The process as claimed in claim 19, wherein the purity of the eprosartan acetate is about above 99.5%.

### Claim 21 (depends on 20)

The process as claimed in claim 20, wherein the purity of the eprosartan acetate is about above 99.9%.

### Claim 22 (depends on 18)

The process as claimed in claim 18, wherein the crude eprosartan free base in step (a) is dissolved in acetic acid at a temperature above about 40° C.

### Claim 23 (depends on 22)

The process as claimed in claim 22, wherein the crude eprosartan free base is dissolved in acetic acid at a temperature between 45° C. and 110° C.

### Claim 24 (depends on 23)

The process as claimed in claim 23, wherein the crude eprosartan free base is dissolved in acetic acid at a temperature between 50° C. and 100° C.

### Claim 25 (depends on 18)

The process as claimed in claim 18, wherein the methylene chloride is added to the filtrate in step (b) at a temperature between 0° C. and 40° C.

### Claim 26 (depends on 25)

The process as claimed in claim 25, wherein the methylene chloride is added to the filtrate at a temperature between 10° C. and 40° C.

### Claim 27 (depends on 26)

The process as claimed in claim 26, wherein the methylene chloride is added to the filtrate at a temperature between 15° C. and 35° C.

### Claim 28 (depends on 18)

The process as claimed in claim 18, wherein the precipitated eprosartan acetate crystalline solid in step (c) is collected by filtration or centrifugation.

### Claim 29

Substantially pure eprosartan free base.

### Claim 30 (depends on 29)

The compound as claimed in claim 29, wherein the eprosartan free base has a purity above 99.5%.

### Claim 31 (depends on 30)

The compound as claimed in claim 30, wherein the eprosartan free base has a purity above about 99.7%.

### Claim 32 (depends on 31)

The compound as claimed in claim 31, wherein the eprosartan free base has a purity above 99.9%.

### Claim 33 (depends on 29)

A process for the preparation of substantially pure eprosartan free base as defined in claim 29, which comprises:
a. suspending eprosartan acetate in water;
b. adjusting the pH of the suspension to about 6.7-7.5 with a base; and
c. collecting the precipitated substantially pure eprosartan base.

### Claim 34 (depends on 33)

The process as claimed in claim 33, wherein the pH of the suspension in step (b) is adjusted to 6.8-7.4.

### Claim 35 (depends on 34)

The process as claimed in claim 34, wherein the pH of the suspension is adjusted to 6.9-7.3.

### Claim 36 (depends on 33)

The process as claimed in claim 33, wherein the base used in step (b) is an organic base or an inorganic base.

### Claim 37 (depends on 36)

The process as claimed in claim 36, wherein the organic base is tributylamine, N,N-dimethylaniline, 4-dimethylaminopyridine, ethyldiisopropyl amine, N-ethylmorpholine, 2,4,6-trimethylpyridine or triethylamine.

### Claim 38 (depends on 36)

The process as claimed in claim 36, wherein the inorganic base is an alkali or alkaline earth metal carbonate or bicarbonate or hydroxide.

### Claim 39 (depends on 38)

The process as claimed in claim 38, wherein the inorganic base is sodium hydroxide or potassium hydroxide.

### Claim 40 (depends on 39)

The process as claimed in claim 39, wherein the inorganic base is sodium hydroxide.

### Claim 41 (depends on 33)

The process as claimed in claim 33, wherein the aqueous solution of sodium hydroxide is used to adjust the pH.

### Claim 42 (depends on 41)

The process as claimed in claim 41, wherein the dilute aqueous sodium hydroxide is used.

### Claim 43 (depends on 33)

The process as claimed in claim 33, wherein the precipitated eprosartan free base in step (c) is collected by filtration or centrifugation.

### Claim 44

A pharmaceutical composition comprising eprosartan mesylate crystalline particles having a specific surface area of from about 0.65 m2/g to about 3 m2/g and one or more pharmaceutically inert excipients.

### Claim 45 (depends on 44)

The pharmaceutical composition as claimed in claim 44, wherein the eprosartan mesylate crystalline particles having mean particle size (D50) ranges from about 7 μm to 50 μm and 90 volume-% of the particles (D90) ranges from about 21 μm to 150 μm.

### Claim 46 (depends on 44)

The pharmaceutical composition as claimed in claim 44, wherein the pharmaceutical composition is selected from a solid dosage form and an oral suspension.

### Claim 47 (depends on 46)

The pharmaceutical composition as claimed in claim 46, wherein solid dosage form includes tablet, capsule, granules and sachet.
